28 Capital

Overview

28 Capital is a Boston-based venture capital firm that focuses on translating cutting-edge scientific discoveries into breakthrough therapies. The firm partners closely with academic founders, top-tier institutions, and principal investigators to identify foundational science and develop it into scalable, patient-focused businesses. Their portfolio includes transformative biotech companies with platform technologies in therapeutics, diagnostics, and synthetic biology. The firm's investment strategy emphasizes a hands-on approach to venture creation, working alongside founders from inception through scale. 28 Capital is co-led by John Boyce and Audrey Warner, who bring deep expertise in venture capital, company creation, and corporate strategy. They have a strong track record of identifying promising scientific inventions and collaborating with scientific founders to unlock and scale world-class technologies. 28 Capital continues to co-invest with leading venture firms, strategics, and institutional limited partners in its mission to accelerate breakthrough science into the clinic and beyond. Their commitment to advancing scientific breakthroughs for patients underscores their dedication to improving healthcare outcomes through innovative investments.

Investment Focus

• Founder(s) must be full-time on the venture
• Scalable product or service addressing a large and growing market opportunity
• Tech-driven or tech-enabled
• Intellectual property must be owned by or exclusively licensed to the venture
• Measurable traction in the form of early adopter revenue, beta testing, pilot/POC, or clinical data
• Pre-seed or seed-stage investments targeting pre-money valuations below $20M
• Potential to generate 10x+ return multiple

Portfolio Companies